GRI Bio, Inc., a development stage biotech company, develops Natural Killer T (NKT) cell-based therapies for liver disease and autoimmunity. Its program includes GRI-0621, an inhibitor of type 1 NKT cells that develops as an oral therapeutic for liver disease. GRI Bio, Inc. was formerly know as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in La Jolla, California. The company trades on NASDAQ exchange. The company headquarter is located in La Jolla, CA. The company was established in the 2009.

TickerGRI
Long NameGRI Bio, Inc.
Short NameGRI Bio